Active ingredient: Ciclesonide 80 µg/inhalation, 160 µg/inhalation ... studies were conducted to evaluate the efficacy of Alvesco in the management of mild-to-severe asthma in patients >12 ...

Alvesco approved for asthma Sepracor has launched Alvesco (ciclesonide) inhalation aerosol for the prophylactic and maintenance treatment of asthma in patients ≥12 years of age. Sepracor has ...

Alvesco approved for asthma The FDA has approved Alvesco (ciclesonide, from Nycomed) inhalation aerosol for the prophylactic and maintenance treatment of asthma in patients ≥12 years of age.

Back to Healio Nonhospitalized patients with COVID-19 who received the inhaled glucocorticoid Alvesco had the same recovery time as those who received placebo, data from a phase 3 trial showed.

Alvesco is an inhaled anti-inflammatory maintenance therapy delivered by a metered-dose inhaler to help control persistent asthma. Through the collaboration with Walgreens, all eligible patients ...

The Phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of Alvesco, a metered-dose inhaler, in non-hospitalized individuals with COVID-19 aged 12 and above.

Pharmacology: Alvesco is a metered-dose oral inhaler product with a dose counter that delivers ciclesonide, a nonhalogenated corticosteroid, to the airways using hydrofluoroalkane-134 as a propellant.